ALIGOS THERAPEUTICS INC (ALGS)
US01626L1052 - Common Stock
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir...
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
What's going on in today's pre-market session
Friday's pre-market session: top gainers and losers
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
Event to feature KOL perspective on emerging MASH therapies
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
Event to feature KOL perspective on emerging MASH therapies...
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical...
Why Is Tharimmune (THAR) Stock Down 8% Today?
Tharimmune stock is falling after the company announced a reverse stock split for THAR shares that goes into effect later today.
Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today?
Aligos Therapeutics stock is falling alongside news of a secondary offering for ALGS that it won't see any proceeds of the sales from.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning!
Aligos Therapeutics files to sell 168.73M shares of common stock (NASDAQ:ALGS)
Read about Aligos Therapeutics filing a prospectus for the resale of over 168 million shares of common stock, not an offer to sell.
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
The thyroid hormone receptor-beta (THR-b) drug ALG-055009: Was well tolerated when oral daily doses up to 1.0 mg were given for 2 weeks in a Phase 1 study...
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Hepatitis B virus e antigen positive (HBeAg+) subjects dosed with once-daily 300mg ALG-000184 + entecavir for up to 48 weeks demonstrated: Dose...